RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/26871599http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/26871599http://www.w3.org/2000/01/rdf-schema#comment"Glioblastoma (GBM) is an aggressive brain tumor which is currently treated with temozolomide (TMZ). Tumors usually become resistant to TMZ and recur; no effective therapy is then available. Monoamine Oxidase A (MAO A) oxidizes monoamine neurotransmitters resulting in reactive oxygen species which cause cancer. This study shows that MAO A expression is increased in human glioma tissues and cell lines. MAO A inhibitors, clorgyline or the near-infrared-dye MHI-148 conjugated to clorgyline (NMI), were cytotoxic for glioma and decreased invasion in vitro. Using the intracranial TMZ-resistant glioma model, clorgyline or NMI alone or in combination with low-dose TMZ reduced tumor growth and increased animal survival. NMI was localized specifically to the tumor. Immunocytochemistry studies showed that the MAO A inhibitor reduced proliferation, microvessel density and invasion, and increased macrophage infiltration. In conclusion, we have identified MAO A inhibitors as potential novel stand-alone drugs or as combination therapy with low dose TMZ for drug-resistant gliomas. NMI can also be used as a non-invasive imaging tool. Thus has a dual function for both therapy and diagnosis."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.org/dc/terms/identifier"doi:10.18632/oncotarget.7283"xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Chen T.C."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Wang W."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Chen K."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Shih J.C."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Yeh T.S."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Hofman F.M."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Olenyuk B.Z."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Jhaveri N."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Kota R."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Groshen S.L."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Kushal S."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/author"Vaikari V.P."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/date"2016"xsd:gYear
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/name"Oncotarget"xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/pages"13842-13853"xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/title"Monoamine oxidase A (MAO A) inhibitors decrease glioma progression."xsd:string
http://purl.uniprot.org/citations/26871599http://purl.uniprot.org/core/volume"7"xsd:string
http://purl.uniprot.org/citations/26871599http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/26871599
http://purl.uniprot.org/citations/26871599http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/26871599
http://purl.uniprot.org/uniprot/#_A0A1W5KJW8-mappedCitation-26871599http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26871599
http://purl.uniprot.org/uniprot/#_Q53EZ0-mappedCitation-26871599http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26871599
http://purl.uniprot.org/uniprot/#_P21397-mappedCitation-26871599http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26871599